Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30


Immunogenicity of pembrolizumab in patients with advanced tumors.

van Vugt MJH, Stone JA, De Greef RHJMM, Snyder ES, Lipka L, Turner DC, Chain A, Lala M, Li M, Robey SH, Kondic AG, De Alwis D, Mayawala K, Jain L, Freshwater T.

J Immunother Cancer. 2019 Aug 8;7(1):212. doi: 10.1186/s40425-019-0663-4.


p38 inhibition and not MK2 inhibition enhances the secretion of chemokines from TNF-α activated rheumatoid arthritis fibroblast-like synoviocytes.

Dulos J, Wijnands FP, van den Hurk-van Alebeek JA, van Vugt MJ, Rullmann JA, Schot JJ, de Groot MW, Wagenaars JL, van Ravestein-van Os R, Smets RL, Vink PM, Hofstra CL, Nelissen RL, van Eenennaam H.

Clin Exp Rheumatol. 2013 Jul-Aug;31(4):515-25. Epub 2013 Apr 3.


The high-affinity IgG receptor, FcgammaRI, plays a central role in antibody therapy of experimental melanoma.

Bevaart L, Jansen MJ, van Vugt MJ, Verbeek JS, van de Winkel JG, Leusen JH.

Cancer Res. 2006 Feb 1;66(3):1261-4.


CpG oligodeoxynucleotides enhance FcgammaRI-mediated cross presentation by dendritic cells.

Bevaart L, Van Ojik HH, Sun AW, Sulahian TH, Leusen JH, Weiner GJ, Van De Winkel JG, Van Vugt MJ.

Int Immunol. 2004 Aug;16(8):1091-8. Epub 2004 Jun 10.


CpG-A and B oligodeoxynucleotides enhance the efficacy of antibody therapy by activating different effector cell populations.

van Ojik HH, Bevaart L, Dahle CE, Bakker A, Jansen MJ, van Vugt MJ, van de Winkel JG, Weiner GJ.

Cancer Res. 2003 Sep 1;63(17):5595-600.


Liposomal meningococcal B vaccination: role of dendritic cell targeting in the development of a protective immune response.

Arigita C, Bevaart L, Everse LA, Koning GA, Hennink WE, Crommelin DJ, van de Winkel JG, van Vugt MJ, Kersten GF, Jiskoot W.

Infect Immun. 2003 Sep;71(9):5210-8.


Non-linear antigenic regions in epidermal growth factor (EGF) and transforming growth factor alpha (TGF alpha) studied by EGF-TGF alpha chimaeras.

van de Poll ML, van Rotterdam W, Gadellaa MM, Stortelers C, van Vugt MJ, van Zoelen EJ.

Biochem J. 2000 Jul 1;349(Pt 1):267-74.


Superagonistic activation of ErbB-1 by EGF-related growth factors with enhanced association and dissociation rate constants.

Lenferink AE, van Zoelen EJ, van Vugt MJ, Grothe S, van Rotterdam W, van De Poll ML, O'Connor-McCourt MD.

J Biol Chem. 2000 Sep 1;275(35):26748-53.


The FcgammaRIa (CD64) ligand binding chain triggers major histocompatibility complex class II antigen presentation independently of its associated FcR gamma-chain.

van Vugt MJ, Kleijmeer MJ, Keler T, Zeelenberg I, van Dijk MA, Leusen JH, Geuze HJ, van de Winkel JG.

Blood. 1999 Jul 15;94(2):808-17.


The alternatively spliced CD64 transcript FcgammaRIb2 does not specify a surface-expressed isoform.

van Vugt MJ, Reefman E, Zeelenberg I, Boonen G, Leusen JH, van de Winkel JG.

Eur J Immunol. 1999 Jan;29(1):143-9.


The linear C-terminal regions of epidermal growth factor (EGF) and transforming growth factor-alpha bind to different epitopes on the human EGF receptor.

Lenferink AE, De Roos AD, Van Vugt MJ, Van de Poll ML, Van Zoelen EJ.

Biochem J. 1998 Nov 15;336 ( Pt 1):147-51.


FcgammaRIa-gamma-chain complexes trigger antibody-dependent cell-mediated cytotoxicity (ADCC) in CD5+ B cell/macrophage IIA1.6 cells.

Van Vugt MJ, Van den Herik-Oudijk IE, Van de Winkel JG.

Clin Exp Immunol. 1998 Sep;113(3):415-22.


Differential endocytic routing of homo- and hetero-dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers.

Lenferink AE, Pinkas-Kramarski R, van de Poll ML, van Vugt MJ, Klapper LN, Tzahar E, Waterman H, Sela M, van Zoelen EJ, Yarden Y.

EMBO J. 1998 Jun 15;17(12):3385-97.


Superagonistic behaviour of epidermal growth factor/transforming growth factor-alpha chimaeras: correlation with receptor routing after ligand-induced internalization.

Lenferink AE, Kramer RH, van Vugt MJ, Königswieser M, Di Fiore PP, van Zoelen EJ, van de Poll ML.

Biochem J. 1997 Nov 1;327 ( Pt 3):859-65.


Insertion of Argos sequences into the B-loop of epidermal growth factor results in a low-affinity ligand with strong agonistic activity.

van de Poll ML, van Vugt MJ, Lenferink AE, van Zoelen EJ.

Biochemistry. 1997 Jun 17;36(24):7425-31. Erratum in: Biochemistry 1997 Sep 23;36(38):11542.


The Fc receptor gamma-chain and the tyrosine kinase Syk are essential for activation of mouse platelets by collagen.

Poole A, Gibbins JM, Turner M, van Vugt MJ, van de Winkel JG, Saito T, Tybulewicz VL, Watson SP.

EMBO J. 1997 May 1;16(9):2333-41.


A drying-down technique for the spreading of mammalian meiocytes from the male and female germline.

Peters AH, Plug AW, van Vugt MJ, de Boer P.

Chromosome Res. 1997 Feb;5(1):66-8. No abstract available.


Binding of PE-CY5 conjugates to the human high-affinity receptor for IgG (CD64)

van Vugt MJ, van den Herik-Oudijk IE, van de Winkle JG.

Blood. 1996 Sep 15;88(6):2358-61. No abstract available.


FcR gamma-chain is essential for both surface expression and function of human Fc gamma RI (CD64) in vivo.

van Vugt MJ, Heijnen IA, Capel PJ, Park SY, Ra C, Saito T, Verbeek JS, van de Winkel JG.

Blood. 1996 May 1;87(9):3593-9.


Antigen targeting to myeloid-specific human Fc gamma RI/CD64 triggers enhanced antibody responses in transgenic mice.

Heijnen IA, van Vugt MJ, Fanger NA, Graziano RF, de Wit TP, Hofhuis FM, Guyre PM, Capel PJ, Verbeek JS, van de Winkel JG.

J Clin Invest. 1996 Jan 15;97(2):331-8.


A single amino acid exchange, Arg-45 to Ala, generates an epidermal growth factor (EGF) mutant with high affinity for the chicken EGF receptor.

van de Poll ML, Lenferink AE, van Vugt MJ, Jacobs JJ, Janssen JW, Joldersma M, van Zoelen EJ.

J Biol Chem. 1995 Sep 22;270(38):22337-43.


Differential expression of a new dominant agouti allele (Aiapy) is correlated with methylation state and is influenced by parental lineage.

Michaud EJ, van Vugt MJ, Bultman SJ, Sweet HO, Davisson MT, Woychik RP.

Genes Dev. 1994 Jun 15;8(12):1463-72.


A molecular model for the genetic and phenotypic characteristics of the mouse lethal yellow (Ay) mutation.

Michaud EJ, Bultman SJ, Klebig ML, van Vugt MJ, Stubbs LJ, Russell LB, Woychik RP.

Proc Natl Acad Sci U S A. 1994 Mar 29;91(7):2562-6.


Characterization of resistance mechanisms to cis-diamminedichloroplatinum(II) in three sublines of the CC531 colon adenocarcinoma cell line in vitro.

Oldenburg J, Begg AC, van Vugt MJ, Ruevekamp M, Schornagel JH, Pinedo HM, Los G.

Cancer Res. 1994 Jan 15;54(2):487-93.


Effects of temperature on the interaction of cisplatin and carboplatin with cellular DNA.

Los G, van Vugt MJ, den Engelse L, Pinedo HM.

Biochem Pharmacol. 1993 Oct 5;46(7):1229-37.


A rationale for carboplatin treatment and abdominal hyperthermia in cancers restricted to the peritoneal cavity.

Los G, Smals OA, van Vugt MJ, van der Vlist M, den Engelse L, McVie JG, Pinedo HM.

Cancer Res. 1992 Mar 1;52(5):1252-8.


The influence of hyperthermia on the uptake of cisplatin in the rat cervical spinal cord.

Sminia P, Los G, Hendriks JJ, van Vugt MJ, Haveman J, González González D.

Eur J Cancer. 1992;28A(6-7):1139-43.


Supplemental Content

Loading ...
Support Center